$30 vs $300 Semaglutide: Where the Money Goes (2026)

$30 vs $300 Semaglutide: Where the Money Goes

Industry-context information only. This article describes peptide supply-chain economics and regulatory structure based on FDA records, Drug Master File filings, and published industry data. It is not medical advice. Peptide sources, regulatory categories, and vendor practices change frequently. Consult a licensed physician for personal medical decisions.

Compounded semaglutide from a telehealth clinic costs $200–400 per month. The same molecule from a research-peptide vendor costs $25–35 per month at current prices. That's a 7–11× gap for a chemically identical compound — and it's not because one is real and the other is fake.

It's because the price difference is paying for downstream infrastructure that doesn't exist on the research side. Some of that infrastructure is real safety value. Some of it is telehealth-platform marketing economics. Honest decision-making requires knowing which is which.

This article breaks down: where compounded GLP-1 actually comes from, where research-peptide bottles actually come from, what the regulatory difference is between them, and where every dollar of the markup goes.

The cost gap is real and bigger than most people realize

Current 2026 pricing, drawn from live vendor data:

Semaglutide

~$27/month at 2.4 mg/week (Ion Peptide 30 mg vial $84 effective, ~$2.81/mg)

$200–400/month (Hims, Ro, Form Health, Henry Meds, TrimRx, Mochi)

$1,000–1,400/month (branded prescription semaglutide at retail without insurance)

Tirzepatide

~$53/month at 10 mg/week (EZ Peptides 60 mg×10 kit $799 effective, ~$1.33/mg)

$300–500/month

$1,000–1,200/month

Retatrutide

~$30/month at 4 mg/week (EZ Peptides 24 mg×10 kit $664 effective, ~$2.77/mg)

Not yet available compounded (still phase 3)

Not yet approved

Even the compounded route — the "supervised" middle tier — is 7–11× more expensive than the research path. That's the gap this article is about. The branded retail prices ($1,000+/month) are a separate problem driven by US drug pricing policy and aren't the question here.

Both supply chains start at the same place

For sema, tirz, and most GLP-1 family peptides, the bulk active pharmaceutical ingredient (API) comes overwhelmingly from a small set of large Chinese peptide synthesis houses. This is publicly documented through FDA Drug Master File filings, which any pharmacist or buyer can look up.

The major Chinese peptide API manufacturers serving both regulated and gray channels include:

Hangzhou Enogen Biotech — explicitly listed on the FDA "Green List" for semaglutide and tirzepatide; serves 503B compounding pharmacies

Hybio Pharmaceutical

WuXi TIDES (the peptide arm of WuXi AppTec, a major Chinese CDMO)

Sichuan Pengting Technology

Hangzhou Go Top Peptide Biotech

Sinopep Biopharma

AmbioPharm

Polypeptide Group (multi-site, includes Switzerland and US, but does manufacture in China)

So the hypothesis "both compounded and research peptides come from China" is largely correct. What it misses is that not all Chinese factories are equivalent.

The two-tier Chinese factory reality

There are two distinct tiers of Chinese peptide manufacturers, and the legal sourcing wall between them is the most important fact in this article.

Tier 1 — FDA-registered. These facilities have filed a Drug Master File (DMF) with the FDA, are registered under section 510 of the Federal Food, Drug, and Cosmetic Act, and have been inspected. Their API can legally enter the US drug supply chain. 503B compounding pharmacies are legally required to source bulk drug substances from this tier. Examples include Enogen and a small number of others on the FDA's published Green List.

Tier 2 — unregistered. These facilities have no DMF, no §510 registration, and have not been inspected by FDA. They sell bulk peptide API into the export market, often labeled "research use only" or "not for human consumption" to sidestep regulatory exposure. Per a Partnership for Safe Medicines analysis of 239 illegal API shipments to the US, a majority of Chinese manufacturers exporting "semaglutide" API are not even permitted to distribute that API for human use within China. This is the most damning data point in the entire supply-chain story.

Research-peptide vendors source from both tiers. The reputable ones — those that publish independent third-party COAs and have visible community track records — increasingly source from Tier 1. The cheap ones don't, because Tier 2 material is dramatically less expensive at the bulk level.

A 503B compounding pharmacy cannot legally use Tier 2 material. That's a regulatory hard wall, not an industry preference.

Where every dollar of the $300 compounded price actually goes

Here's a defensible decomposition of a typical $300/month compounded semaglutide subscription, drawn from published telehealth-company financials, compounding-pharmacy fee disclosures, and known marketing economics:

Tier-1 bulk API (FDA-registered Chinese factory)

$5–15

The chemically same molecule that's $0.50–2 in the gray market; small markup for traceable supply chain

Compounding pharmacy fee

$20–40

Sterility testing, potency assay, lot release, USP <797> sterile compounding, packaging, regulatory overhead

Provider visit fees + ongoing follow-up

$40–80

Licensed clinician time for initial consult and monthly check-ins

Medical liability insurance

$10–20

$5K–15K per provider per year, amortized across patient panel

Customer acquisition cost (paid ads)

$50–100

Google/Meta ads. CAC for a telehealth GLP-1 patient is typically $200–500, amortized over 3–6 months avg retention

Brand and content marketing

$20–50

Hims spent over $1B on marketing in 2024 across all categories; GLP-1 share is significant

Platform tech, payments, customer support

Telehealth software, prescribing platform, support team

Net margin to telehealth company

$30–80

Operating profit. VC-backed companies target 70–80% gross margin and use the resulting cash for growth

Two takeaways from this decomposition.

First: roughly $80–150 of the $300 monthly price is real, value-add cost — FDA-registered API supplier, lot-by-lot finished-product testing, sterility/endotoxin verification on the vial that ships, clinical oversight from a licensed provider, and FDA recourse if something goes wrong. The size of the upgrade depends on what you're comparing it to. Versus a cheap research vendor that ships only the supplier's own COA, it's a meaningful safety upgrade. Versus a reputable research vendor that publishes independent third-party COAs (Janoshik or equivalent), the upgrade is narrower — primarily chain-of-custody, sterility on the finished vial, and clinical supervision rather than the molecule itself.

Second: roughly $130–200 of the $300 monthly price is platform economics — paid customer acquisition, brand marketing, and the margin requirements of a VC-funded growth company. None of that adds safety value to your individual prescription. It's the cost of running a marketing-intensive telehealth business at scale, passed to the patient.

So the honest answer to "is the markup greedy or structural?" is both. Some of it pays for safety the gray market can't deliver. Some of it pays for Hims's Super Bowl ad. The patient who can't tell the difference gets billed for both.

What you're actually getting at each tier

Independent of the price, what is the safety profile of each path? A side-by-side that doesn't pretend there are only two options:

Bulk API from FDA-registered Chinese factory

Required by law

Not required (USP monograph compliance instead)

Often, with reputable vendors

Rarely

Lot-by-lot finished-product testing

Pharmacist's discretion

No (vendor relies on supplier COA)

No

Sterility and endotoxin testing on finished product

Independent third-party COA (Janoshik, etc.)

N/A — built into chain

N/A

Yes if reputable

No (vendor's own COA only)

Written prescription from a licensed clinician

Yes

FDA recourse if something goes wrong

None

Typical monthly cost

$300–500

$200–350

$25–80

$15–40

Practical user profile

Insured, supervised

Cash-pay supervised

Self-managed researcher

Self-managed bargain hunter

The "reputable research vendor with third-party COA" tier is the one most often missed in discussions that pretend the choice is binary. It's not the same risk profile as 503B compounded — there's no licensed clinician monitoring you, no sterility testing on the finished vial, no FDA recourse — but it's also not the same risk profile as a $15 unbranded vial from a vendor you've never heard of. Independent third-party COAs are publicly verifiable; the gap between vendors that publish them and vendors that don't is the most decision-relevant signal in the research-peptide market.